Cat. No.: HY-114570

Tiazofurin

(Synonyms: NSC 286193; Riboxamide)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Tiazofurin (NSC 286193) is a synthetic nucleoside analogue with antineoplastic activity. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH). Tiazofurin enhances the autosecretion of IL-6 in K562 cells. Tiazofurin also has anti-orthopoxvirus and anti-variola activities. Tiazofurin can be used for the study of leukemia and lung cancer.

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 60084-10-8
Formula: C₉H₁₂N₂O₅S
Molecular Weight:260.27

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Tiazofurin Chemical Structure

CAS No.: 60084-10-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	24 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line	[PMID: 9171883]
ACHN	IC₅₀	>100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma	[PMID: 9171883]
B16	IC₅₀	16.2 μM Compound: 1 (tiazofurin)	Inhibitory concentration against B16 melanoma cell lines Inhibitory concentration against B16 melanoma cell lines	[PMID: 7562914]
B16	IC₅₀	16.2 μM Compound: tiazofurin	In vitro inhibitory activity against B16 murine melanoma cells In vitro inhibitory activity against B16 murine melanoma cells	[PMID: 2120442]
CCRF-CEM	IC₅₀	10 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia	[PMID: 9171883]
CCRF-SB	IC₅₀	7.5 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia	[PMID: 9171883]
CHO-K1	IC₅₀	6.4 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary cells Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary cells	[PMID: 9171883]
HeLa	IC₅₀	100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma	[PMID: 9171883]
HeLa	IC₅₀	3.82 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HeLa	IC₅₀	3.82 μM Compound: 1, Tiazofurin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23010263]
HeLa	IC₅₀	3.82 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26859071]
HeLa	IC₅₀	4.76 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against HeLa cells after 24 hrs by MTT assay Cytotoxicity against HeLa cells after 24 hrs by MTT assay	[PMID: 16908146]
HeLa	IC₅₀	4.76 μM Compound: 1	Antiproliferative activity against human HeLa cell line Antiproliferative activity against human HeLa cell line	[PMID: 16495053]
HL-60	IC₅₀	0.19 μM Compound: 1	Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HL-60	IC₅₀	0.19 μM Compound: 1, Tiazofurin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23010263]
HL-60	IC₅₀	0.19 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 26859071]
HL-60	IC₅₀	1.84 μM Compound: 1, tiazofurin	Cytotoxicity against human HL60 cell line after 48 hrs by MTT assay Cytotoxicity against human HL60 cell line after 48 hrs by MTT assay	[PMID: 17543526]
HL-60	IC₅₀	2.5 μM Compound: 1 (tiazofurin)	Inhibitory concentration range against human HL-60 cell line Inhibitory concentration range against human HL-60 cell line	[PMID: 7562914]
HL-60	IC₅₀	6.1 μM Compound: tiazofurin	In vitro inhibitory activity against HL-60 human promyelocytic leukemia cells In vitro inhibitory activity against HL-60 human promyelocytic leukemia cells	[PMID: 2120442]
HL-60	IC₅₀	8.7 μM Compound: 1 (tiazofurin)	Inhibitory concentration against HL-60 human promyelocytic leukemia Inhibitory concentration against HL-60 human promyelocytic leukemia	[PMID: 7562914]
HL-60	IC₅₀	9.32 μM Compound: 1	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16495053]
HL-60	IC₅₀	9.32 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit HL-60 cell growth Concentration required to inhibit HL-60 cell growth	[PMID: 12951086]
HT-29	IC₅₀	0.26 μM Compound: 1	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HT-29	IC₅₀	0.26 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26859071]
HT-29	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23010263]
HT-29	IC₅₀	0.89 μM Compound: 1, tiazofurin	Cytotoxicity against human HT29 cell line after 48 hrs by MTT assay Cytotoxicity against human HT29 cell line after 48 hrs by MTT assay	[PMID: 17543526]
HT-29	IC₅₀	1.01 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against HT29 cells after 24 hrs by MTT assay Cytotoxicity against HT29 cells after 24 hrs by MTT assay	[PMID: 16908146]
HT-29	IC₅₀	1.01 μM Compound: 1	Antiproliferative activity against human HT29 cell line Antiproliferative activity against human HT29 cell line	[PMID: 16495053]
HT-29	IC₅₀	1.01 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit HT-29 cell growth Concentration required to inhibit HT-29 cell growth	[PMID: 12951086]
HT-29	IC₅₀	100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma	[PMID: 9171883]
Jurkat	IC₅₀	0.04 μM Compound: 1	Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Jurkat	IC₅₀	0.04 μM Compound: 1, Tiazofurin	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 23010263]
Jurkat	IC₅₀	0.04 μM Compound: 1; Tiazofurin	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 26859071]
Jurkat	IC₅₀	0.14 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against Jurkat cells after 24 hrs by MTT assay Cytotoxicity against Jurkat cells after 24 hrs by MTT assay	[PMID: 16908146]
Jurkat	IC₅₀	0.51 μM Compound: 1, tiazofurin	Cytotoxicity against human Jurkat T cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 48 hrs by MTT assay	[PMID: 17543526]
K562	IC₅₀	1.89 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
K562	IC₅₀	1.89 μM Compound: 1; Tiazofurin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 26859071]
K562	IC₅₀	2.09 μM Compound: 1, Tiazofurin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 23010263]
K562	IC₅₀	2.5 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against K562, human erythroid leukemia Compound was tested for antiproliferative activity against K562, human erythroid leukemia	[PMID: 9171883]
K562	IC₅₀	2.98 μM Compound: 1, tiazofurin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 17543526]
K562	IC₅₀	3 μM Compound: 1, TR	Concentration of the Antiproliferative compound required for the 50% inhibition of Growth against K562 cells Concentration of the Antiproliferative compound required for the 50% inhibition of Growth against K562 cells	[PMID: 11806722]
K562	IC₅₀	3 μM Compound: TF (1)	Antiproliferative activity against K562 erythroid leukemic cells was determined. Antiproliferative activity against K562 erythroid leukemic cells was determined.	[PMID: 9258359]
K562	IC₅₀	3 μM Compound: TR	Tested for inhibition of growth in human erythroleukemia K-562 cells. Tested for inhibition of growth in human erythroleukemia K-562 cells.	[PMID: 9111303]
K562	IC₅₀	4.16 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit K562 cell growth Concentration required to inhibit K562 cell growth	[PMID: 12951086]
K562	IC₅₀	4.5 μM Compound: 1 (tiazofurin)	Inhibitory concentration against K562 human myelogenous leukemia cell line Inhibitory concentration against K562 human myelogenous leukemia cell line	[PMID: 7562914]
K562	IC₅₀	5.29 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 16908146]
K562	IC₅₀	5.29 μM Compound: 1	Antiproliferative activity against human K562 cell line Antiproliferative activity against human K562 cell line	[PMID: 16495053]
L1210	IC₅₀	2.9 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia	[PMID: 9171883]
L1210	IC₅₀	6.2 μM Compound: tiazofurin	In vitro inhibitory activity against L1210 murine lymphocytic leukemia cells In vitro inhibitory activity against L1210 murine lymphocytic leukemia cells	[PMID: 2120442]
L1210	IC₅₀	7.4 μM Compound: 1 (tiazofurin)	Inhibitory concentration against L1210 murine lymphocytic leukemia Inhibitory concentration against L1210 murine lymphocytic leukemia	[PMID: 7562914]
Lewis lung carcinoma cell line	IC₅₀	1.5 μM Compound: 1 (tiazofurin)	Inhibitory concentration against LLC Lewis lung carcinoma Inhibitory concentration against LLC Lewis lung carcinoma	[PMID: 7562914]
LoVo	IC₅₀	>128 μM Compound: 1 (tiazofurin)	Inhibitory concentration against LoVo human colon adenocarcinoma cell lines Inhibitory concentration against LoVo human colon adenocarcinoma cell lines	[PMID: 7562914]
MCF7	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23010263]
MCF7	IC₅₀	1.78 μM Compound: 1; Tiazofurin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26859071]
MCF7	IC₅₀	6.39 μM Compound: 1, tiazofurin	Cytotoxicity against human MCF7 cell line after 48 hrs by MTT assay Cytotoxicity against human MCF7 cell line after 48 hrs by MTT assay	[PMID: 17543526]
MCF7	IC₅₀	7.98 μM Compound: 1	Antiproliferative activity against human MCF7 cell line Antiproliferative activity against human MCF7 cell line	[PMID: 16495053]
MCF7	IC₅₀	8.49 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit MCF-7 cell growth Concentration required to inhibit MCF-7 cell growth	[PMID: 12951086]
MDA-MB-231	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23010263]
MOLT-4	IC₅₀	5.2 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia	[PMID: 9171883]
MRC5	IC₅₀	0.36 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31557614]
MRC5	IC₅₀	0.36 μM Compound: 1, Tiazofurin	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 23010263]
MRC5	IC₅₀	0.36 μM Compound: 1; Tiazofurin	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 26859071]
MRC5	IC₅₀	0.49 μM Compound: 1, tiazofurin	Cytotoxicity against human MRC5 cell line after 48 hrs by MTT assay Cytotoxicity against human MRC5 cell line after 48 hrs by MTT assay	[PMID: 17543526]
MRC5	IC₅₀	0.85 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against MRC5 cells after 24 hrs by MTT assay Cytotoxicity against MRC5 cells after 24 hrs by MTT assay	[PMID: 16908146]
MRC5	IC₅₀	0.85 μM Compound: 1	Antiproliferative activity against human MRC5 cell line Antiproliferative activity against human MRC5 cell line	[PMID: 16495053]
MRC5	IC₅₀	0.85 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit MRC-5 cell growth Concentration required to inhibit MRC-5 cell growth	[PMID: 12951086]
P388	IC₅₀	16.7 μM Compound: tiazofurin	In vitro inhibitory activity against P388 murine lymphocytic leukemia cells In vitro inhibitory activity against P388 murine lymphocytic leukemia cells	[PMID: 2120442]
P388	IC₅₀	2.2 μM Compound: 1 (tiazofurin)	Inhibitory concentration against P388 murine lymphocytic leukemia cell lines Inhibitory concentration against P388 murine lymphocytic leukemia cell lines	[PMID: 7562914]
Raji	IC₅₀	16.06 μM Compound: 1, tiazofurin	Cytotoxicity against human Raji cells after 48 hrs by MTT assay Cytotoxicity against human Raji cells after 48 hrs by MTT assay	[PMID: 17543526]
Raji	IC₅₀	5.28 μM Compound: 1	Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Raji	IC₅₀	5.28 μM Compound: 1, Tiazofurin	Cytotoxicity against human Raji cells after 72 hrs by MTT assay Cytotoxicity against human Raji cells after 72 hrs by MTT assay	[PMID: 23010263]
Raji	IC₅₀	5.28 μM Compound: 1; Tiazofurin	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 26859071]
Raji	IC₅₀	8.2 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma	[PMID: 9171883]
WIL2-NS	IC₅₀	5.7 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells	[PMID: 9171883]

In Vitro

Tiazofurin (10 μM, 0-3 days) affects growth kinetics and promotes erythroid differentiation in K562 human leukemia cells, while significantly increasing the percentage of benzidine-positive cells and elevating glycophorin A (GpA) expression^[1].
Tiazofurin (10 μM, 2 days) enhances IL-6 autosecretion in K562 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tiazofurin (200-700 mg/kg, i.p., qd, days 1-9) exerts significant anti-tumor efficacy in sensitive murine transplanted tumor models (P388/L1210 leukemia in CDF1 mice, Lewis lung carcinoma in B6C3F1 mice)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

leukemia cells (P388/L1210) and Lewis lung carcinoma cells were intravenously inoculated into B6C3F1 mice or CDF1 mice^[2]
Dosage:

200, 700 mg/kg
Administration:

i.p., qd days 1-9
Result:

Exerted significant anti-tumor efficacy in sensitive murine transplanted tumor models (P388/L1210 leukemia in CDF1 mice, Lewis lung carcinoma in B6C3F1 mice).

Chemical Information

CAS No. 60084-10-8
Appearance Solid
Molecular Weight 260.27
Formula C₉H₁₂N₂O₅S
Color White to off-white
SMILES

O=C(N)C1=CSC([C@@H]2O[C@@H]([C@H]([C@H]2O)O)CO)=N1
Synonyms

NSC 286193; Riboxamide
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All

Sort by:

Journal Impact Factor

Nat Commun

Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. [Abstract]

2025 Mar 18;16(1):2641. PMID: 40102405

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (480.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8422 mL

19.2108 mL

38.4216 mL

5 mM

0.7684 mL

3.8422 mL

7.6843 mL

10 mM

0.3842 mL

1.9211 mL

3.8422 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Talley CJ, et al. Tiazofurin-induced autosecretion of IL-6 and hemoglobin production in K562 human leukemia cells. Am J Hematol. 1997 Apr;54(4):301-5. [Content Brief]

[2]. Ahluwalia GS, et al. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol. 1984 Apr 15;33(8):1195-203. [Content Brief]

[3]. Tricot G, Jayaram HN, Weber G, Hoffman R. Tiazofurin: biological effects and clinical uses. Int J Cell Cloning. 1990;8(3):161-170. [Content Brief]

[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8422 mL	19.2108 mL	38.4216 mL	96.0541 mL
	5 mM	0.7684 mL	3.8422 mL	7.6843 mL	19.2108 mL
	10 mM	0.3842 mL	1.9211 mL	3.8422 mL	9.6054 mL
	15 mM	0.2561 mL	1.2807 mL	2.5614 mL	6.4036 mL
	20 mM	0.1921 mL	0.9605 mL	1.9211 mL	4.8027 mL
	25 mM	0.1537 mL	0.7684 mL	1.5369 mL	3.8422 mL
	30 mM	0.1281 mL	0.6404 mL	1.2807 mL	3.2018 mL
	40 mM	0.0961 mL	0.4803 mL	0.9605 mL	2.4014 mL
	50 mM	0.0768 mL	0.3842 mL	0.7684 mL	1.9211 mL
	60 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6009 mL
	80 mM	0.0480 mL	0.2401 mL	0.4803 mL	1.2007 mL
	100 mM	0.0384 mL	0.1921 mL	0.3842 mL	0.9605 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tiazofurin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Orthopoxvirus Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Tiazofurin

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tiazofurin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Orthopoxvirus Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Tiazofurin

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tiazofurin Related Classifications

HY-114570 Related Classifications